Bidirectional crosstalk between cancer cells and cancer-associated fibroblasts in mixed organoid system elicits transcriptomic characteristics of pancreatic cancer with potential therapeutic vulnerabilities

Jae-Il Choi; Min Jae Yang; Kyoung-Jin Woo; So Hyun Park; Dakeun Lee; Seokhwi Kim

doi:10.1002/ctm2.1597

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (2) : e1597 DOI: 10.1002/ctm2.1597

LETTER TO THE JOURNAL

Bidirectional crosstalk between cancer cells and cancer-associated fibroblasts in mixed organoid system elicits transcriptomic characteristics of pancreatic cancer with potential therapeutic vulnerabilities

Jae-Il Choi ¹^,²
, Min Jae Yang ³
, Kyoung-Jin Woo ¹^,²
, So Hyun Park ¹^,²
, Dakeun Lee ¹^,²^,^†
, Seokhwi Kim ¹^,²^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Jae-Il Choi, Min Jae Yang, Kyoung-Jin Woo, So Hyun Park, Dakeun Lee, Seokhwi Kim. Bidirectional crosstalk between cancer cells and cancer-associated fibroblasts in mixed organoid system elicits transcriptomic characteristics of pancreatic cancer with potential therapeutic vulnerabilities. Clinical and Translational Medicine, 2024, 14(2): e1597 DOI:10.1002/ctm2.1597

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1-2):324-338.

[2]	Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12(6):319-334.

[3]	Seino T, Kawasaki S, Shimokawa M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell. 2018;22(3):454-467 e6.

[4]	Grossman JE, Muthuswamy L, Huang L, et al. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer. Clin Cancer Res. 2022;28(4):708-718.

[5]	Seppala TT, Zimmerman JW, Suri R, et al. Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. Clin Cancer Res. 2022;28(15):3296-3307.

[6]	Raghavan S, Winter PS, Navia AW, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021;184(25):6119-6137.e26.

[7]	Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol Med. 2023;29(6):439-453.

[8]	von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol. 2017;10(1):76.

[9]	Schuth S, Le Blanc S, Krieger TG, et al. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Exp Clin Cancer Res. 2022;41(1):312.

[10]	Kim S, Woo KJ, Yang CM, et al. Simultaneous establishment of pancreatic cancer organoid and cancer-associated fibroblast using a single-pass endoscopic ultrasound-guided fine needle biopsy specimen. Dig Endosc. 2023;35(7):918-926.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.